Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block

NCT ID: NCT05022160

Last Updated: 2021-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-10

Study Completion Date

2021-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bladder irrigation with a 3 way foley catheter is an important component of post operative management of transurethral bladder surgeries. But it is associated with a high incidence of bladder discomfort. Catheter related bladder discomfort (CRBD) doesn't respond to the orthodox opioid pain medication and is greatly distressful to the patients postoperatively, adversely affecting the quality of recovery often requiring administration of additional pain medication thereby increasing treatment costs, patient dissatisfaction and longer hospital stays. Several systemic agents have been used to reduce CRBD, but they have many side effects. A trial has been planned to find a way of reducing CRBD avoid distressing systemic side effects

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

INTRODUCTION:

Trans urethral resection of prostate (TURP) and trans urethral resection of bladder tumor (TURBT) are the two most commonly performed endourological procedures associated with complication rates of 10% and 11% respectively.1 This relatively high percentage of complications can be owed to the amount of blood loss that occurs in these surgical procedures and can cause subsequent clot retention. Irrigation attached with three-way large bore urinary catheters is employed in order to avoid this clot retention.2 Catheter related bladder discomfort (CRBD) is a consequence of these large bore urinary catheters irritating the bladder mucosa causing involuntary bladder contractions being mediated by urothelial muscarinic receptors.3 The incidence of CRBD ranges from 47% to 90%.4 CRBD induced by indwelling urinary catheter is characterized by supra-pubic discomfort and a burning sensation in the urethra accompanied by an intense urge to void and increased urinary frequency.5 CRBD doesn't respond to the orthodox opioid pain medication and is greatly distressful to the patients postoperatively, adversely affecting the quality of recovery often requiring administration of additional pain medication thereby increasing treatment costs, patient dissatisfaction and longer hospital stays.3-5 The sensory supply of urethra and bladder neck is carried by Pudendal nerve. It originates from the ventral rami of the anterior nerve roots arising from sacral segments S2 to S4. Therefore theoretically, CRBD can be prevented by applying Pudendal Nerve Block (PNB).5 Xiaoqiang et al in 2017 reported that pudendal nerve block significantly reduced incidence of post-operative CRBD with administration of pudendal nerve block as compared to controls. The frequency of postoperative CRBD was at 63% in PNB versus 82% in control group at 30 minutes which was statistically significant (p=0.004). Similarly, the frequency of CRBD at 2 hours was 64% in PNB and 90% in control group (p˂0.001); and the frequency of CRBD at 8 hours was 58% in PNB and 79% in control group (p=0.003) respectively coinciding with the duration of action of Ropivacaine. Beyond that time there was no statistically significant difference between the two groups.5

RATIONALE:

The rationale of this study is that there is no previous study on this specific topic in the Pakistan. Thus, the findings of my study will help to determine the efficacy of pudendal nerve block in preventing CRBD in our population and will help improve evidence-based practices in patients undergoing TURP and TURBT.

OBJECTIVES:

"To compare between spinal anesthesia with pudendal nerve block versus spinal anesthesia alone in terms of frequency of post-operative CRBD and its severity in patients undergoing TURP and TURBT"

OPERATIONAL DEFINITIONS:

1. CATHETER RELATED BLADDER DISCOMFORT CRBD will be defined as presence of supra-pubic discomfort and a burning sensation in the urethra accompanied by an intense urge to void.
2. PUDENDAL NERVE BLOCK PNB is achieved by Infiltration of .5% ropivacaine in 5ml increments, maximum of 10 ml bilaterally, around Pudendal nerve on both sides under nerve stimulator guidance via two separate punctures 3 and 9 o'clock; approximately 3.5 to 4 cm from the center of the anus after making lithotomy position and aseptic preparation of the skin.
3. NUMERIC RATING SCALE FOR PAIN Numeric Rating Scale for Pain (NRSP) is a continuous scale of pain intensity, consisting of a straight line 10 cm long between the two end-points from 0-10. The patient will specify their level of pain by indicating a position along this line, as detailed in Annexure C. Pain will be scored as no pain (0), mild pain (\<4 cm), moderate pain (4-7 cm) and severe pain (\>7 cm).

HYPOTHESIS:

Spinal anesthesia and Pudendal Nerve Block are better than spinal anesthesia alone in preventing post-operative CRBD in patients undergoing TURP and TURBT.

MATERIAL AND METHODS:

1. STUDY DESIGN: Randomized controlled clinical trial.
2. SETTING: Armed Forces Institute of Urology, Rawalpindi.
3. DURATION OF STUDY: 6 Months after approval of synopsis
4. SAMPLE SIZE: Sample size calculated using WHO sample size calculator

1. Power of Test = 95%.
2. Level of Significance = 5%
3. Anticipated population proportion 1 = 63% 5
4. Anticipated population proportion 2 = 82% 5
5. Minimum sample size in each group (n) = 125 patients in each group.
6. Total Sample size = 250 patients.
5. SAMPLING TECHNIQUE: Non-probability consecutive sampling.

SAMPLE SELECTION:

1. INCLUSION CRITERIA:

1. Male patients.
2. Age \>18 years
3. Patients undergoing TURP \& TURBT
4. No history of chronic pain
5. ASA I, II \& III
2. EXCLUSION CRITERIA:

1. Female gender
2. Ischemic Heart Disease
3. Chronic Obstructive Pulmonary Disease
4. Coagulopathy
5. Mental Disorder
6. ASA IV \& V The above-mentioned factors will act as confounders introducing bias in the study thus excluded.

DATA COLLECTION PROCEDURE:

A Total of 250 patients from Armed Forces Institute of Urology, Rawalpindi undergoing TURP or TURBT who will meet the inclusion and exclusion criterion will be enrolled in the study after taking permission from hospital ethical review committee and approval of synopsis from CPSP REU. Written informed consent will be taken from patients included in the study attached as Annexure A.

Patients will be randomly divided into 2 groups; group A and group B containing 125 patients each by lottery method. Group A patients will be administered bilateral pudendal nerve block with 0.5% Ropivacaine after giving spinal anesthesia while group B patients will only be given spinal anesthesia before undergoing TURP or TURBT.

Patient demographics will be documented before the surgery. Postoperatively all the patients will be observed at intervals of 30 minutes, 08 and 24 hours for development of any post-operative CRBD and its severity. Data in both the groups will be recorded on a predesigned proforma of questionnaire attached in the end as Annexure B.

All patients will be given due respect and their comfort will be taken care of during examination. The exclusion criteria will be strictly followed to control confounders and bias in the study.

DATA ANALYSIS PLAN:

Data will be entered in and analyzed by SPSS Version 16. Mean and standard deviation will be calculated for the quantitative variables i.e. Age, BMI etc. Qualitative variables like gender, ASA grade and CRBD severity will be expressed as frequency and percentages. Effect modifiers like age, BMI and ASA grade will be controlled by stratification. Frequency of CRBD in both the groups will be compared by applying post stratification Chi square test. P value ≤ 0.05 will be taken as significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Neoplasm Prostatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group P

Patients in this group will receive bilateral pudendal nerve block after spinal anesthesia- before starting the surgery

Group Type EXPERIMENTAL

pudendal nerve block

Intervention Type DRUG

All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine

Group C

Patients in this group will only receive spinal anesthesia before starting the surgery

Group Type PLACEBO_COMPARATOR

pudendal nerve block

Intervention Type DRUG

All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pudendal nerve block

All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male patients.
* Age \>18 years
* Patients undergoing TURP \& TURBT under spinal anesthesia
* No history of chronic pain
* ASA I, II \& III

Exclusion Criteria

* Female gender
* Ischemic Heart Disease
* Chronic Obstructive Pulmonary Disease
* Coagulopathy
* Mental Disorder
* ASA IV \& V
* Conversion of spinal anesthesia to general anesthesia
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Armed Forces Hospital, Pakistan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

arshad khushdil

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Madiha Ahmed

Islamabad, , Pakistan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Madiha Ahmed

Role: primary

923345366225

References

Explore related publications, articles, or registry entries linked to this study.

Patel HD, Ball MW, Cohen JE, Kates M, Pierorazio PM, Allaf ME. Morbidity of urologic surgical procedures: an analysis of rates, risk factors, and outcomes. Urology. 2015 Mar;85(3):552-9. doi: 10.1016/j.urology.2014.11.034.

Reference Type BACKGROUND
PMID: 25733265 (View on PubMed)

Xiaoqiang L, Xuerong Z, Juan L, Mathew BS, Xiaorong Y, Qin W, Lili L, Yingying Z, Jun L. Efficacy of pudendal nerve block for alleviation of catheter-related bladder discomfort in male patients undergoing lower urinary tract surgeries: A randomized, controlled, double-blind trial. Medicine (Baltimore). 2017 Dec;96(49):e8932. doi: 10.1097/MD.0000000000008932.

Reference Type BACKGROUND
PMID: 29245259 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Uro-Adm-Trg-1/IRB/2021/122

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.